Overview

The Gene Technology Act 2000 was enacted to provide a framework for the regulation of gene technology in Australia, aiming to protect human health and the environment while facilitating the responsible development of biotechnology. The Act was introduced to address the need for a comprehensive legislative structure to manage the risks and benefits associated with genetically modified organisms (GMOs). The Act was passed by the Australian Parliament and is administered by the Office of the Gene Technology Regulator (OGTR), whose primary policy objective is to ensure that gene technology activities in Australia are conducted safely and ethically. The OGTR is currently assessing a licence application for a field trial of genetically modified cotton designed for insect resistance and herbicide tolerance, with the goal of evaluating its agronomic performance and pest resistance under field conditions. The proposed trial, if approved, would take place across several Australian states and is intended to contribute to the development and production of GM cotton for future regulated releases, provided further approvals are granted.

Scope and Application

The Gene Technology Act 2000, as it pertains to the proposed field trial of genetically modified cotton by Monsanto Australia Limited, applies to the entities involved in the application and the regulatory processes that govern gene technology in Australia. The Act establishes a framework to safeguard the health and safety of individuals and the environment by identifying and managing risks associated with gene technology. The proposed field trial of insect-resistant and herbicide-tolerant cotton aims to assess the agronomic performance and pest resistance of genetically modified cottons under field conditions, while also developing the GM cottons and producing seed for future releases, subject to further regulatory approvals. This trial, set to take place across cotton-growing areas in New South Wales, Queensland, Northern Territory, Victoria, and Western Australia from March 2017 to July 2021, is subject to strict conditions that limit the size, location, and duration of the release, as well as the spread and persistence of the GMOs and the introduced genetic material. The Act’s regulatory reach is national, with the Gene Technology Regulator overseeing the application and consultation process, ensuring compliance with the legislative framework and protecting public and environmental interests.

Key Provisions

The legislation in question, specifically C2016G01509, pertains to the assessment of a genetically modified (GM) cotton field trial application submitted by Monsanto Australia Limited. Section 60 of the Gene Technology Act 2000 outlines the process for field trials of genetically modified organisms (GMOs) and requires the Regulator to consider the application alongside a Risk Assessment and Risk Management Plan (RARMP). The RARMP for the proposed trial of GM cotton, genetically modified for insect resistance and herbicide tolerance, has been prepared and is available for public consultation (section 61). This plan evaluates the potential risks to human health and the environment, concluding that the proposed release poses negligible risk (section 62). Under the Act, the obligations of the applicant, Monsanto Australia Limited, include submitting a comprehensive application for the field trial and ensuring that the trial adheres to the conditions specified in the licence, should it be granted (section 60). The company must also provide ongoing updates and reports on the trial’s progress and any unforeseen issues to the Regulator (section 65). Additionally, the Regulator has a duty to assess the application rigorously, consider public submissions, and decide whether to issue a licence with specific conditions to mitigate any identified risks (section 63). Failure to comply with the provisions of the Act or the conditions of the licence can result in significant consequences. Offences under the Act may include unauthorised release of GMOs, non-compliance with licence conditions, or failure to report incidents as required. The penalties for breaches can be substantial, with maximum fines reaching up to $1.1 million for corporations and $220,000 for individuals, in addition to potential imprisonment terms (section 106). Furthermore, the Regulator has the authority to impose additional administrative penalties and can take legal action to enforce compliance, ensuring that any risks associated with the trial are managed effectively.